Enzo Medico
Molecular Biology · 2007–2017
A researcher in the Science corpus: 5 papers; trusts 10 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 42 citations into it
- Artificial Intelligence — 5 citations into it
Whom Enzo Medico trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from Enzo Medico's perspective
Ordered by how strongly the researchers Enzo Medico trusts endorse each paper. Same corpus, a different order for every researcher.
- Computational identification of cis-regulatory elements associated with groups of functionally related genes in Saccharomyces cerevisiae. (Journal of Molecular Biology)
- Data clustering: a review
- Validating clustering for gene expression data (Bioinform.)
- Nonlinear dimensionality reduction by locally linear embedding.
- Exploring the conditional coregulation of yeast gene expression through fuzzy k-means clustering (Genome Biology)
- Computational cluster validation in post-genomic data analysis (Bioinform.)
- Fuzzy C-means Method for Clustering Microarray Data (Bioinform.)
- ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors (Nature Reviews. Cancer)
- Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated… (Journal of Clinical Oncology)
- KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. (Journal of Clinical Oncology)
Their papers
- FLAME, a novel fuzzy clustering method for the analysis of DNA microarray data (2007) — 548 citations
- Interrogating open issues in cancer precision medicine with patient-derived xenografts (2017) — 601 citations
- Monitoring clonal evolution and resistance to EGFR blockade in the blood of metastatic colorectal cancer patients (2015) — 997 citations
- Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer (2012) — 1,835 citations
- A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. (2011) — 894 citations